COVID-19 has the potential to have a dramatic impact on 30 June 2020 financial reporting period end. National Life Sciences and Technology Leader, Michael Cunningham and Partner, Brock Mackenzie discuss the ramifications to impairment assessments and testing.

COVID-19 - Impairment Considerations For Technology And Life Sciences Companies

From business strategy, to industry innovation and economic landscape analysis, we’ve brought together our experts to unpack how Australian businesses are doing things differently.

Share COVID-19 - Impairment Considerations For Technology And Life Sciences Companies

Sign up to save your podcasts

COVID-19 - Impairment Considerations For Technology And Life Sciences Companies

COVID-19 - Impairment Considerations For Technology And Life Sciences Companies

More shows like Beyond the Numbers with Grant Thornton

We are retail